Dimethylcurcumin nano preparation and application thereof
By coupling with amino polyethylene glycol monomethyl ether and preparing nanoparticles, dimethyl curcumin nanopreparation was prepared in combination with thin film hydration method, which solved the problem of low bioavailability caused by its hydrophobicity and achieved high drug loading and pH-sensitive drug release significantly enhance the killing effect on prostate cancer cells.
Patent Information
- Application Number
- CN202410997515.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-12
AI Technical Summary
Dimethyl curcumin is difficult to pass through the cell membrane due to its hydrophobicity, resulting in low bioavailability, which limits its application in the treatment of prostate cancer. The existing nanoparticle encapsulation method is costly and has not been effectively improved. Report on degree.
Dimethyl curcumin prodrug nanoparticles were prepared by amide bond coupling with amino polyethylene glycol monomethyl ether, and nanoformula loaded with free dimethyl curcumin was prepared by film hydration method, which had pH sensitivity Drug release and high encapsulation rate.
The high drug loading and good biocompatibility of dimethyl curcumin are achieved, which promotes drug release in tumor cells and significantly improves the killing effect on tumor cells.
Smart Images

Figure CN118924909A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of drug delivery systems, and in particular to a dimethylcurcumin nano preparation and application thereof. Background Art
[0002] In recent years, prostate cancer has become one of the most common cancers, and the cancer-related mortality rate is also high. In clinical prostate cancer treatment, androgen deprivation therapy remains the main treatment option for patients with advanced prostate cancer. However, this treatment often causes prostate cancer to develop into castration-resistant prostate cancer, which ultimately leads to the patient's death.
[0003] Dimethoxycurcumin (DMC) is a curcumin derivative with multiple biological activities. It shows great potential in the treatment of androgen receptor-related diseases such as prostate cancer, benign prostatic hypertrophy, and bladder cancer by enhancing the degradation of androgen receptors. In particular, in the treatment of prostate cancer, dimethylcurcumin can control castration-resistant prostate cancer that has developed enzalutamide resistance and inhibit the growth and metastasis of cancer cells.
[0004] Because dimethyl curcumin is a hydrophobic molecule, it is difficult to effectively pass through the cell membrane, so that the human body has a lower utilization rate to it, which seriously limits its application. At present, there are reports of using high molecular materials such as PEG and lecithin to encapsulate curcumin, and there are also reports of using dimethyl curcumin and methoxy polyethylene glycol aldehyde groups to covalently bind to obtain new nanoparticles, and using this nanoparticle to encapsulate dimethyl curcumin. But the method directly uses dimethyl curcumin to react with PEG, and the preparation cost is higher. Therefore, synthesizing dimethyl curcumin from scratch and combining it with PEG to form new nanoparticles is an effective method to improve the bioavailability of dimethyl curcumin. At present, there is no report to enhance its water solubility and bioavailability by synthesizing dimethyl curcumin from scratch and coupling it with a PEG carrier. Summary of the invention
[0005] The present invention first prepares dimethyl curcumin prodrug nanoparticles, that is, a compound formed by covalently coupling aminopolyethylene glycol monomethyl ether and dimethyl curcumin with chloroacetic acid. The specific preparation method includes:
[0006] (1) Preparation of acetylacetone derivatives: directly heating acetylacetone and chloroacetic acid in a solvent to obtain acetylacetone derivatives
[0007]
[0008] The specific preparation method is as follows: dissolving chloroacetic acid and potassium carbonate in a solvent, adding acetylacetone after stirring, heating for reaction, and after the reaction is completed, removing the solvent by rotary evaporation, and purifying by column chromatography to obtain a dimethyl curcumin derivative;
[0009] The molar ratio of acetylacetone to chloroacetic acid is 1:1 to 1:2; the temperature of the heating reaction is 25 to 60° C.; the time of the heating reaction is 8 to 12 hours; and the solvent is DMF.
[0010] (2) Preparation of dimethyl curcumin derivatives: directly heating the acetylacetone derivative prepared in step (1) and 3,4-dimethoxybenzaldehyde in a solvent to obtain dimethyl curcumin derivatives. The dimethyl curcumin derivatives formed can be represented by cDMC.
[0011]
[0012]
[0013] The preparation method is specifically as follows: dissolving the acetylacetone derivative prepared in step (1) with 3,4-dimethoxybenzaldehyde, boron oxide, tributyl borate and n-butylamine in a solvent, heating for reaction, adding 20% acetic acid aqueous solution to precipitate the product after the reaction is completed, recrystallizing with methanol, and transferring to a freeze dryer to avoid light and freeze-drying to obtain a dimethyl curcumin derivative;
[0014] The molar ratio of the acetylacetone derivative to 3,4-dimethoxybenzaldehyde is 1:2; the temperature of the heating reaction is 25 to 80° C.; the time of the heating reaction is 2 to 5 hours; and the solvent is DMF.
[0015] (3) Preparation of dimethylcurcumin prodrug nanoparticles: The dimethylcurcumin derivative prepared in step (2) is reacted with aminopolyethylene glycol monomethyl ether (mPEG-NH2) to obtain dimethylcurcumin prodrug nanoparticles.
[0016] The formed dimethylcurcumin prodrug nanoparticles can be represented by cDMC-mPEG.
[0017]
[0018] The specific preparation method is as follows: dissolving the dimethyl curcumin derivative prepared in step (2) and aminopolyethylene glycol monomethyl ether in a solvent, heating for reaction, removing the solvent by rotary evaporation after the reaction is completed, adding distilled water to dissolve it, transferring it to a dialysis bag with a molecular weight cutoff of 3500Da, dialyzing it in water, centrifuging the dialyzate after the dialysis is completed, taking the supernatant, freezing it at -80°C for 2h, transferring it to a freeze dryer for freeze drying, and obtaining dimethyl curcumin prodrug nanoparticles.
[0019] Wherein, the average molecular weight of aminopolyethylene glycol monomethyl ether is 1kDa to 20kDa;
[0020] The molar ratio of the methoxy polyethylene glycol aldehyde group to the dimethyl curcumin derivative is 1:1 to 1:10.
[0021] The temperature of the heating reaction is preferably 25 to 40° C.; the time of the heating reaction is 12 to 48 hours; and the solvent is DCM.
[0022] The dialysis treatment time is 48 to 96 hours.
[0023] The specific synthetic route for preparing dimethylcurcumin prodrug nanoparticles of the present invention is shown in Formula 1.
[0024]
[0025] The dimethyl curcumin prodrug nanoparticles prepared by the invention are used for preparing a water-soluble dimethyl curcumin nano preparation, that is, a nano preparation loaded with free dimethyl curcumin is prepared by a thin film hydration method. The specific preparation method comprises the following steps: adding the dimethyl curcumin prodrug nanoparticles and the free dimethyl curcumin into a solvent, stirring and dissolving them at room temperature, removing the solvent by rotary evaporation and forming a film, adding ultrapure water, ultrasonically dispersing, centrifuging and obtaining a supernatant, and freeze-drying to obtain the nano preparation loaded with free dimethyl curcumin.
[0026] The mass ratio of dimethylcurcumin prodrug nanoparticles to dimethylcurcumin is 10:1 to 10:3; the stirring time is 2 to 5 hours; the solvent is anhydrous methanol or anhydrous ethanol;
[0027] The supernatant is frozen at -80°C for 2 hours, and transferred to a freeze dryer to be freeze-dried in the dark, thereby obtaining the nano preparation loaded with free dimethyl curcumin.
[0028] The prodrug nanoparticles or nano preparations prepared by the invention are used for preparing medicaments for resisting prostate cancer and liver cancer.
[0029] Beneficial effects of the present invention:
[0030] (1) The present invention uses acetylacetone, chloroacetic acid and 3,4-dimethoxybenzaldehyde as raw materials to synthesize dimethyl curcumin derivatives at a lower cost.
[0031] (2) The present invention is the first to couple a dimethyl curcumin derivative and amino polyethylene glycol monomethyl ether through an amide bond. The compound can self-assemble into nanoparticles in ultrapure water and can load free dimethyl curcumin with high encapsulation efficiency and drug loading.
[0032] (3) The nanoformulation loaded with free dimethyl curcumin provided by the present invention has the property of pH-sensitive drug release, and can promote the release of loaded drugs in the acidic microenvironment within tumor cells; it has good biocompatibility and has a stronger killing effect on tumor cells than free dimethyl curcumin. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1This is a hydrogen nuclear magnetic resonance spectrum of the dimethylcurcumin prodrug prepared in Example 1 of the present invention;
[0034] Figure 2 This is an infrared spectrum of the dimethylcurcumin prodrug prepared in Example 1 of the present invention;
[0035] Figure 3 This is a particle size distribution diagram of dimethylcurcumin prodrug prepared in Example 1 of the present invention self-assembled into nanoparticles in ultrapure water;
[0036] Figure 4 This is an electron micrograph of the dimethylcurcumin prodrug prepared in Example 1 of the present invention self-assembled into nanoparticles in ultrapure water. DETAILED DESCRIPTION
[0037] The specific implementation of the present invention is further described in detail below in conjunction with the accompanying drawings and examples. The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention.
[0038] Example 1
[0039] (1) 1 g (10.0 mmol) of acetylacetone and 4.14 g (30.0 mmol) of potassium carbonate were dissolved in 15 mL of DMF, 1.89 g (20.0 mmol) of chloroacetic acid was added, and the mixture was stirred at 50° C. for 12 hours to obtain a reaction solution A;
[0040] (2) adding 150 ml of distilled water to dissolve the reaction solution A obtained in step (1), extracting with ethyl acetate (EA), collecting the organic phase, drying it with anhydrous sodium sulfate, filtering to remove the solid, and distilling the solution under reduced pressure and purifying it by column chromatography to obtain a yellow liquid which is an acetylacetone derivative;
[0041] (3) The acetylacetone derivative obtained in step (2) was dissolved in 6 mL of DMF, 1.95 g (11.76 mmol) of 3,4-dimethoxybenzaldehyde, 0.31 g (4.41 mmol) of boron oxide, 2.71 g (11.76 mmol) of tributyl borate and 0.22 g (2.94 mmol) of n-butylamine were added, and the mixture was stirred at 80° C. for 3 hours to obtain a reaction solution B;
[0042] (4) Add 60 mL of 20% acetic acid aqueous solution to the reaction solution B obtained in step (3), continue heating and stirring for 2 hours, filter, collect the orange-red residue, add 2 mL of anhydrous methanol and recrystallize at 60° C., and the obtained orange-red solid is a dimethylcurcumin derivative.
[0043] (5) The dimethylcurcumin derivative obtained in step (4) was dissolved in 10 mL of DCM, and 189.2 mg (0.09 mmol) of aminopolyethylene glycol monomethyl ether, 108.8 mg (0.54 mmol) of EDCI and 5.8 mg (0.05 mmol) of DMAP were added, and the mixture was stirred at 40° C. for 24 hours to obtain a reaction solution C.
[0044] (6) The reaction solution C obtained in step (5) was subjected to rotary evaporation to remove the solvent, and 6 mL of ultrapure water was added to dissolve it. The solution was dialyzed with ultrapure water for 3 days, wherein the molecular weight cutoff of the dialysis bag was 3500 Da. After the dialysis was completed, the solution was frozen in a -80°C refrigerator for 2 hours, and then transferred to a freeze dryer to be freeze-dried in the dark. The obtained dark yellow solid was dimethylcurcumin prodrug nanoparticles (99.9 mg, yield: 43.0%).
[0045] Test Example 1
[0046] The chemical structure of the target compound dimethylcurcumin prodrug in Example 1 is confirmed:
[0047] The chemical structure of the target compound prepared in Example 1 was confirmed by hydrogen nuclear magnetic resonance spectroscopy and infrared spectroscopy. Figure 2 and Figure 3 The hydrogen nuclear magnetic resonance spectrum and infrared spectrum of the target compound prepared in Example 1 of the present invention.
[0048] Depend on Figure 2 It can be seen that the NMR spectrum of the dimethyl curcumin derivative corresponds to the methyl hydrogen in the methoxy group and the aromatic hydrogen in the benzene ring and the double bond hydrogen in the double bond at 3.77-3.84, 6.95-7.05, 7.10-7.20, 7.25-7.34, 7.35-7.44, and 7.55-7.71, respectively. The NMR spectrum of the target compound of Example 1 contains both the aromatic hydrogen in the benzene ring derived from dimethyl curcumin and the double bond hydrogen in the double bond, and also contains polyethylene glycol peaks, indicating that the dimethyl curcumin derivative is successfully combined with amino polyethylene glycol monomethyl ether.
[0049] Depend on Figure 3 It can be seen that the dimethyl curcumin prodrug has a peak at 1640 cm -1 A new absorption peak appeared at , which was attributed to the amide bond formed by the combination of dimethyl curcumin derivative and aminopolyethylene glycol monomethyl ether.
[0050] Test Example 2
[0051] Self-assembly behavior of the dimethylcurcumin prodrug obtained in Example 1:
[0052] Preparation of the experimental solution: Weigh 2 mg of the dimethyl curcumin prodrug prepared in Example 1 of the present invention, add 2 mL of ultrapure water, and ultrasonically disperse for 5 min to prepare a 1 mg / mL aqueous solution; weigh 20 mg of phosphotungstic acid, dissolve in 1 mL of ultrapure water to prepare a 2% phosphotungstic acid aqueous solution.
[0053] 1 mL of the dimethylcurcumin prodrug aqueous solution prepared in this example was taken, and the particle size distribution of the dimethylcurcumin prodrug assembly prepared in this example was measured by dynamic light scattering.
[0054] Figure 4 The particle size distribution diagram of the dimethylcurcumin prodrug assembly prepared in this example is shown in Figure 2. The experimental results show that the particle size of the dimethylcurcumin prodrug assembly prepared in this example is normally distributed, the particle size distribution is relatively narrow, and the average diameter is about 130 nm.
[0055] 50 μL of the dimethylcurcumin prodrug aqueous solution prepared in this example was added dropwise onto a copper mesh covered with a carbon support film, dried naturally in air, and then stained with 2% phosphotungstic acid for 2 min. The morphology of the dimethylcurcumin prodrug assembly prepared in this example was observed using a transmission electron microscope.
[0056] Figure 4 The electron microscope image of the dimethyl curcumin prodrug assembly prepared in this example. The experimental results show that the dimethyl curcumin prodrug assembly prepared in this example is approximately spherical, has the morphological characteristics of nanoparticles, has a uniform particle size distribution, and has a diameter of about 130 nm.
[0057] Test Example 3
[0058] Drug loading behavior of dimethylcurcumin prodrug self-assembled nanoparticles:
[0059] Drug loading method: 10 mg of the dimethylcurcumin prodrug prepared in Example 1 of the present invention and 1.0 mg of dimethylcurcumin were weighed and dissolved in 3 mL of methanol, stirred at room temperature for 4 hours, the solvent was removed by rotary evaporation, 2 mL of ultrapure water was added, ultrasonicated for 5 minutes, and the supernatant was centrifuged to obtain DMC@cDMC-mPEG (15.3%) nanoparticle solution.
[0060] 10 mg of the dimethylcurcumin prodrug prepared in Example 1 of the present invention and 2.0 mg of dimethylcurcumin were weighed and dissolved in 3 mL of methanol. The mixture was stirred at room temperature for 4 hours, and the solvent was removed by rotary evaporation. 2 mL of ultrapure water was added, and the mixture was ultrasonicated for 5 minutes. The supernatant was centrifuged to obtain a DMC@cDMC-mPEG (17.7%) nanoparticle solution.
[0061] 10 mg of the dimethylcurcumin prodrug prepared in Example 1 of the present invention and 3.0 mg of dimethylcurcumin were weighed and dissolved in 3 mL of methanol, stirred at room temperature for 4 hours, the solvent was removed by rotary evaporation, 2 mL of ultrapure water was added, ultrasonicated for 5 minutes, and the supernatant was taken by centrifugation to obtain a DMC@cDMC-mPEG (7.7%) nanoparticle solution.
[0062] The drug loading of the drug-loaded nanoparticles prepared in this embodiment was measured by an ELISA instrument. The drug-loaded nanoparticles prepared in this embodiment were weighed to obtain a mass W1, and the mass W2 of dimethyl curcumin in the drug-loaded nanoparticles prepared in this embodiment was measured by an ELISA instrument. The drug loading (DLC) was calculated using the formula DLC (%) = W2 / W1×100%.
[0063] The feed amount of dimethyl curcumin is set to W3, the feed amount of dimethyl curcumin prodrug prepared in Example 1 of the present invention is set to W4, and the theoretical drug loading (DLC t )Using Official DLC t (%) = W3 / (W3+W4)×100%.
[0064] The encapsulation efficiency (EE) is calculated using the formula EE (%) = DLC / DLC t ×100%.
[0065] The drug loading amount and encapsulation efficiency of dimethylcurcumin in the DMC@cDMC-mPEG (15.3%) nanoparticles prepared in this example were 15.3% and 75.6%, respectively; the drug loading amount and encapsulation efficiency of dimethylcurcumin in the DMC@cDMC-mPEG (17.7%) nanoparticles prepared in this example were 17.7% and 40.5%, respectively; the drug loading amount and encapsulation efficiency of dimethylcurcumin in the DMC@cDMC-mPEG (7.7%) nanoparticles prepared in this example were 7.7% and 11.5%, respectively.
[0066] Test Example 4
[0067] Particle size and charge characterization of cDMC-mPEG prepared in Example 1, DMC@cDMC-mPEG (15.3%), DMC@cDMC-mPEG (17.7%), and DMC@cDMC-mPEG (7.7%) prepared in Experimental Example 3:
[0068] Sample preparation: Weigh 2 mg each of cDMC-mPEG prepared in Example 1 of the present invention, DMC@cDMC-mPEG (15.3%), DMC@cDMC-mPEG (17.7%), and DMC@cDMC-mPEG (7.7%) prepared in Experimental Example 3, dissolve them in 2 mL of ultrapure water, ultrasonically disperse for 5 minutes, and prepare a 1 mg / mL aqueous solution.
[0069] Take 1 mL of the aqueous solutions of cDMC-mPEG, DMC@cDMC-mPEG (15.3%), DMC@cDMC-mPEG (17.7%), and DMC@cDMC-mPEG (7.7%) prepared in this experimental example, and use dynamic light scattering to measure the particle size and charge of the aqueous solutions of cDMC-mPEG, DMC@cDMC-mPEG (15.3%), DMC@cDMC-mPEG (17.7%), and DMC@cDMC-mPEG (7.7%) prepared in this experimental example.
[0070] It can be seen from Table 1 that with the increase of drug loading, the particle size of the sample increases accordingly, and the polydispersity index of the sample is less than 0.5, indicating that the sample has good dispersion.
[0071] Table 1. Particle size and charge characterization results of cDMC-mPEG prepared in Example 1, DMC@cDMC-mPEG (15.3%), DMC@cDMC-mPEG (17.7%) and DMC@cDMC-mPEG (7.7%) prepared in Experimental Example 3.
[0072]
[0073] Test Example 5
[0074] Drug release behavior of DMC@cDMC-mPEG (15.3%) nanoparticles prepared in Experimental Example 3:
[0075] Preparation of drug solution: The DMC@cDMC-mPEG (15.3%) solution prepared in Experimental Example 3 of the present invention was diluted with ultrapure water to prepare an aqueous solution with a dimethylcurcumin concentration of 180 μg / mL.
[0076] Preparation of release solution:
[0077] (1) Release solution I (PBS pH 7.4, Tween 80 content 1.0%): weigh 2.16 g disodium hydrogen phosphate dodecahydrate, 0.26 g potassium dihydrogen phosphate, and 10 g Tween-80, add ultrapure water to dissolve, and make up to 1000 mL, then adjust the pH to 7.4 with dilute hydrochloric acid.
[0078] (2) Release solution II (PBS pH 5.0, Tween 80 content 1.0%): weigh 2.16 g disodium hydrogen phosphate dodecahydrate, 0.26 g potassium dihydrogen phosphate, and 10 g Tween-80, add ultrapure water to dissolve, and make up to 1000 mL, then adjust the pH to 5.0 with dilute hydrochloric acid.
[0079] 1mL of drug solution was loaded into a dialysis bag (molecular weight cutoff: 3500Da), sealed, and then the dialysis bag containing the drug solution was immersed in 30mL of release solution, and then placed in a shaker for shaking at a temperature of 37°C and a speed of 180rpm. 1mL of release solution was taken out at 4, 8, 24, 36, 48, 60 and 72h time points, and 1mL of the corresponding release solution was added. Three groups of drug release experiments were performed in parallel in each release solution. The drug release experiment was carried out under light-proof conditions throughout the process. The drug concentration of the released solution was determined by an ELISA instrument and the cumulative release amount was calculated. The cumulative release amount results of the DMC@cDMC-mPEG (15.3%) solution prepared in Experimental Example 3 are shown in Table 2.
[0080] Table 2. Cumulative release results of DMC@cDMC-mPEG (15.3%) solution prepared in Experimental Example 3.
[0081]
[0082]
[0083] As shown in Table 2, the DMC@cDMC-mPEG (15.3%) solution prepared in Experimental Example 3 has a significantly faster release rate in the release solution II with a pH of 5.0 than in the release solution I with a pH of 7.4, and is released more completely in the release solution II. Under the condition of the release solution I with a pH of 7.4, the total drug release of the DMC@cDMC-mPEG (15.3%) solution prepared in Experimental Example 3 in 96 hours is only 26.89%, while under the condition of the release solution II with a pH of 5.0, the total drug release of the DMC@cDMC-mPEG (15.3%) solution prepared in Experimental Example 3 in 96 hours can reach 37.23%. This shows that the DMC@cDMC-mPEG (15.3%) solution prepared in Experimental Example 3 of the present invention has the characteristics of pH-responsive drug release.
[0084] Test Example 6
[0085] In vitro antitumor activity of dimethylcurcumin prodrug cDMC-mPEG prepared in Experimental Example 1 and DMC@cDMC-mPEG (15.3%) nanoparticles prepared in Experimental Example 3:
[0086] Preparation of experimental drugs: The dimethyl curcumin prodrug prepared in Experimental Example 1 of the present invention was dissolved in ultrapure water, ultrasonicated for 5 min, and prepared into a dimethyl curcumin content of 1 mg / mL aqueous solution; free dimethyl curcumin was dissolved in dimethyl sulfoxide to prepare a 1 mg / mL dimethyl curcumin solution.
[0087] The HepG-2 cell killing experiment was divided into three groups, free dimethylcurcumin experimental group (DMC), dimethylcurcumin prodrug experimental group cDMC-mPEG prepared in Experimental Example 1, and DMC@cDMC-mPEG (15.3%) nanoparticle experimental group prepared in Experimental Example 3. Each experimental group was diluted by DMEM medium to a concentration of 1.563, 3.125, 6.25, 12.5, 25 and 50 μg / mL and added to a 96-well plate and incubated with cells, with about 5000 cells per well, and each concentration in each experimental group was repeated in 4 wells, and then cultured for 24h and 48h.
[0088] The cell survival rate was detected by MTT method, and the cells incubated with blank medium were taken as 100% survival rate. The killing effects of free dimethylcurcumin experimental group (DMC), dimethylcurcumin prodrug experimental group cDMC-mPEG prepared in Experimental Example 1, and DMC@cDMC-mPEG (15.3%) nanoparticle experimental group prepared in Experimental Example 3 on HepG-2 cells are shown in Table 3.
[0089] Table 3. IC values of free dimethylcurcumin, cDMC-mPEG prepared in Example 1 and DMC@cDMC-mPEG (15.3%) prepared in Experimental Example 3 in 22Rv1 cells and HepG2 cells 50 value.
[0090]
[0091] As shown in Table 3, in the experimental group incubated for 24 hours, the cell survival rates of the dimethyl curcumin prodrug and DMC@cDMC-mPEG (15.3%) nanoparticle experimental groups were lower than those of the free dimethyl curcumin experimental group, and the inhibitory effect on the growth of HepG2 cells was more obvious. 50 The half inhibition concentration (IC 50 7.06μg / mL and 4.26μg / mL, respectively), indicating that the dimethyl curcumin prodrug prepared in Example 1 and the DMC@cDMC-mPEG (15.3%) nanoparticles experimental group prepared in Experimental Example 3 have stronger HepG2 cell killing effects than free dimethyl curcumin. In the experimental group incubated for 48h, the cell survival rates of the dimethyl curcumin prodrug and DMC@cDMC-mPEG (15.3%) nanoparticles experimental groups were lower than those of the free dimethyl curcumin experimental group, and the inhibitory effects on HepG2 cell growth were more obvious. Compared with the free dimethyl curcumin experimental group (IC 50The half inhibition concentration (IC 50 The results showed that the dimethyl curcumin prodrug prepared in Example 1 and the DMC@cDMC-mPEG (15.3%) nanoparticles prepared in Experimental Example 3 had better HepG2 cell killing effect than free dimethyl curcumin, and the cell killing effect of DMC@cDMC-mPEG (15.3%) prepared in Experimental Example 3 was stronger.
[0092] The 22Rv1 cell killing experiment was divided into three groups, free dimethylcurcumin experimental group (DMC), dimethylcurcumin prodrug experimental group cDMC-mPEG prepared in Experimental Example 1, and DMC@cDMC-mPEG (15.3%) nanoparticle experimental group prepared in Experimental Example 3. Each experimental group was diluted by 1640 medium to a concentration of 1.563, 3.125, 6.25, 12.5, 25 and 50 μg / mL and added to a 96-well plate and incubated with cells. The number of cells per well was about 5000, and each concentration in each experimental group was repeated 4 wells, and then cultured for 24h and 48h.
[0093] The cell survival rate was detected by MTT method, and the cells incubated with blank medium were taken as 100% survival rate. The killing effects of free dimethylcurcumin experimental group (DMC), dimethylcurcumin prodrug experimental group cDMC-mPEG prepared in Experimental Example 1, and DMC@cDMC-mPEG (15.3%) nanoparticle experimental group prepared in Experimental Example 3 on 22Rv1 cells are shown in Table 3.
[0094] As shown in Table 3, in the experimental group incubated for 24 hours, the cell survival rates of the dimethyl curcumin prodrug and DMC@cDMC-mPEG (15.3%) nanoparticle experimental groups were lower than those of the free dimethyl curcumin experimental group, and the inhibitory effect on the growth of 22Rv1 cells was more obvious. 50 The half inhibition concentration (IC 505.28μg / mL and 2.59μg / mL, respectively), indicating that the dimethyl curcumin prodrug prepared in Example 1 and the DMC@cDMC-mPEG (15.3%) nanoparticles experimental group prepared in Experimental Example 3 have stronger 22Rv1 cell killing effects than free dimethyl curcumin. In the experimental group incubated for 48h, the cell survival rates of the dimethyl curcumin prodrug and DMC@cDMC-mPEG (15.3%) nanoparticle experimental groups were lower than those of the free dimethyl curcumin experimental group, and the inhibitory effect on 22Rv1 cell growth was more obvious. Compared with the free dimethyl curcumin experimental group (IC 50 The half inhibition concentration (IC 50 The results showed that the dimethyl curcumin prodrug prepared in Example 1 and the DMC@cDMC-mPEG (15.3%) nanoparticles prepared in Experimental Example 3 had better 22Rv1 cell killing effect than free dimethyl curcumin, and the cell killing effect of DMC@cDMC-mPEG (15.3%) prepared in Experimental Example 3 was stronger.
[0095] Finally, the method of the present invention is only a preferred embodiment and is not intended to limit the scope of protection of the present invention. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the scope of protection of the present invention.
Claims
1. A dimethyl curcumin nano preparation, characterized in that, The dimethyl curcumin nanoparticles are prepared by adding dimethyl curcumin prodrug nanoparticles and free dimethyl curcumin into a solvent and stirring, and then the nanoparticles loaded with free dimethyl curcumin are prepared by a thin film hydration method, wherein the structural formula of the dimethyl curcumin prodrug nanoparticles is as follows:
2. The dimethyl curcumin nano preparation according to claim 1, characterized in that The preparation method of the dimethylcurcumin prodrug nanoparticles comprises the following steps: (1) adding acetylacetone and chloroacetic acid to a solvent, heating and stirring to react in the dark; after the reaction, removing the solvent by rotary evaporation, separating and purifying by column chromatography to obtain an acetylacetone derivative; (2) adding the acetylacetone derivative prepared in step (1) and 3,4-dimethoxybenzaldehyde to a solvent, heating and stirring to react in the dark; after the reaction, adding 20% acetic acid aqueous solution and stirring, filtering and collecting the residue, and recrystallizing the product to obtain a dimethylcurcumin derivative; (3) adding the dimethyl curcumin derivative and aminopolyethylene glycol monomethyl ether prepared in step (2) to a solvent, heating and stirring to react in the dark; after the reaction, removing the solvent by rotary evaporation, adding distilled water to dissolve, transferring to a dialysis bag with a molecular weight cutoff of 3500Da, dialyzing in water, and after the dialysis, centrifuging the dialyzate, taking the supernatant, and freeze-drying to obtain dimethyl curcumin prodrug nanoparticles.
3. The dimethyl curcumin nano preparation as claimed in claim 2, characterized in that In step (1), the molar ratio of acetylacetone to chloroacetic acid is 1:1-1:2; the solvent is N,N-dimethylformamide; the temperature of the heating and stirring reaction is 25-60° C.; and the time of the heating and stirring reaction is 8-12 hours.
4. The dimethyl curcumin nano preparation according to claim 2, characterized in that, The molar ratio of 3,4-dimethoxybenzaldehyde to acetylacetone derivative in step (2) is 1:2; the solvent is N,N-dimethylformamide; the temperature of the heating and stirring reaction is 25-80° C., and the time of the heating and stirring reaction is 2-5 hours.
5. The dimethyl curcumin nano preparation as claimed in claim 2, characterized in that, The average molecular weight of the aminopolyethylene glycol monomethyl ether in step (3) is 1 kDa to 20 kDa; the molar ratio of the methoxypolyethylene glycol aldehyde group to the dimethyl curcumin derivative is 1:1 to 1:10; the solvent is dichloromethane; the temperature of the heating and stirring reaction is 25 to 40° C., the heating and stirring reaction time is 12 to 48 hours; and the dialysis treatment time is 48 to 96 hours.
6. The dimethyl curcumin nano preparation according to claim 2, characterized in that, The structural formula of the acetylacetone derivative obtained in step (1) is 7. The dimethylcurcumin nanoformulation according to claim 2, characterized in that, The structural formula of the dimethylcurcumin derivative obtained in step (2) is 8. The dimethyl curcumin nano preparation according to claim 2, characterized in that, The mass ratio of the dimethyl curcumin prodrug nanoparticles to free dimethyl curcumin is 1:0.1 to 1:0.3; the solvent is anhydrous methanol or anhydrous ethanol; and the stirring time is 2 to 5 hours.
9. An application of the dimethyl curcumin nano preparation as claimed in claim 1, characterized in that: The dimethylcurcumin nano preparation is used for preparing a medicament for resisting prostate cancer or liver cancer.
